Actinium Pharmaceuticals (ATNM) Income from Continuing Operations (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Income from Continuing Operations of 5724000.0 for Q1 2026, up 64.43% year-over-year from 3481032.95 in Q1 2025, and up 6.38% quarter-over-quarter from 6114000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Income from Continuing Operations for 17 consecutive years, with 5724000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 64.43% year-over-year to 5724000.0; the TTM figure through Mar 2026 stood at 25096000.0 (up 55.51% YoY), while the FY2025 annual figure was 33289000.0, up 12.95% from the prior year.
- Income from Continuing Operations climbed to 5724000.0 in Q1 2026 per ATNM's latest filing, from 6114000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5258000.0 in Q1 2022 and bottomed at 21814000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 11398470.59 across 5 years, with a median of 11341000.0 in 2022.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 123.16% — and 2025, when it jumped 68.16%.
- Actinium Pharmaceuticals' Income from Continuing Operations stood at 11341000.0 in 2022, then rose by 16.44% to 9477000.0 in 2023, then climbed by 28.16% to 6808000.0 in 2024, then rose by 10.19% to 6114000.0 in 2025, then climbed by 6.38% to 5724000.0 in 2026.
- Business Quant data shows ATNM's Income from Continuing Operations at 5724000.0 in Q1 2026, 6114000.0 in Q4 2025, and 6313000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.90 Mn |
| Mar 31, 2026 | -5.72 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -6.31 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Mar 31, 2025 | -16.09 Mn |
| Dec 31, 2024 | -6.81 Mn |
| Sep 30, 2024 | -11.69 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -21.22 Mn |
| Dec 31, 2023 | -9.48 Mn |
| Sep 30, 2023 | -15.02 Mn |
| Jun 30, 2023 | -15.18 Mn |
| Mar 31, 2023 | -11.73 Mn |
| Dec 31, 2022 | -11.34 Mn |
| Sep 30, 2022 | -15.18 Mn |
| Jun 30, 2022 | -7.87 Mn |
| Mar 31, 2022 | -5.26 Mn |
| Dec 31, 2021 | -8.14 Mn |
| Sep 30, 2021 | -8.68 Mn |